FORM 4

Γ

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

or Tuno D

Washington, D.C. 20549 OMB Numb

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

1. Name and Addres GENERAL HILI	2. Issuer Name and Ticker or Trading Symbol iBioPharma, Inc. [IBPM.OB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) C/O IBIOPHARM INNOVATION		3. Date of Earliest Transaction (Month/Day/Year) 02/13/2009						Officer (give title below)	Other (s		
NEWARK, DE 1		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)		Table I -	Non-De	riva	tive Secu	rities	Acqui	ired, Disposed of, or I	Beneficially (Owned	
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execu any	eemed tion Date, if th/Day/Year)	3. Transact Code (Instr. 8 Code	tion	4. Securi Acquired Disposed (Instr. 3, Amount	l (A) d of (l 4 and (A) or	D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of

SEC 1474 (9-02)

information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative	2. Conversion		3A. Deemed Execution Date, if					7. Title and Amount of Underlying				10. Ownership	11. Nature of Indirect		
		(Month/Day/Year)	· · · · ·			1							Beneficial		
-	Price of		(Month/Day/Year)			• •				2	Beneficially		Ownership		
	Derivative		``````````````````````````````````````	Ì		Acquired				` ´			-		(Instr. 4)
	Security					(A) or	-					Following	Direct (D)	Ì.	
						Disposed of					Reported	or Indirect			
						(D)					Transaction(s)	(I)			
					(Instr. 3, 4,							(Instr. 4)	(Instr. 4)		
					and 5)										
											Amount				
								Date	Expiration		or				
								Exercisable		Title	Number				
									Duie		of				
				Code	V	(A)	(D)				Shares				
Stock															
Option	.							(1)		Common Stock		.	60.000		
(right to	\$ 0.2	02/13/2009		Α		60,000		<u>(1)</u>	02/13/2019	Stock	60,000	\$0	60,000	D	
(Hgin to buy)										Stock					
(Juy)															

Reporting Owners

Bonosting Owner Name (Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
GENERAL HILL (Ret) JAMES T. C/O IBIOPHARMA, INC. 9 INNOVATION WAY, SUITE 100 NEWARK, DE 19711	Х							

Signatures

/s/ General James T. Hill	02/17/2009
Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The option vests in three equal annual installments beginning on February 13, 2010.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.